Roche
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Switzerland · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Grenzacherstrasse 124, Basel, Basel-Stad...Phone Number
+41616881111Website
www.roche.comRevenue
$79.8 BillionStock Symbol
ROIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
32
2
4
3
3
2
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The compaRead more
Roche Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Roche your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Roche, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Roche has new funding data
Check out if Roche is spiking on competitors!
Click to see if Roche had a recent Job posting/layoffs
Earning: See what the market has to say on Roche recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Roche has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Roche launches new products
Congratulate Masked Content for being promoted to Masked Content at Roche
Recommended Actions
Reach out to Masked Content who joined Roche as Masked Content
Find 3 more new buyers
Compare Similar Companies to Roche
Compare insights from companies similar to Roche, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$56.7B
10K+
Public
-
1996
DC
Daniela CastanedaImmunology Director, Commercial Operations & Chief of Staff
Company Profile Activity
Activity Insights
Roche is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Roche is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Roche.
Roche Tech Stack
A closer look at the technologies used by Roche
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Roche News & Media
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 (AAIC®) in London on 12-15 July. These data demonstrate how Roche is advancing the development of next-generation medicines and diagnostic tests, driven by a mission to slow, stop or even prevent the progression of Alzheimer’s disease. In total, there are 18 oral and poster presentations.Roche pens $490m Astex breast cancer license deal
Roche’s breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked in recent years.Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial
Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Basel, 02 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive results from the phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibitor, against the approved, first generation KRAS G12C inhibitors sotorasib or adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC). The study met its primary and key secondary endpoint, with divarasib achieving clinically meaningful and statistically significant
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Roche
Sign Up For FreeTo access detailed company insights
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's p... Read More
